Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2-(2,4,5-substituted anilino)pyrimidine compound and application thereof

A compound, C1-C4 technology, applied in 2-(2,4,5-substituted anilino)pyrimidine compounds and its application field

Active Publication Date: 2020-06-19
南京雷正医药科技有限公司 +1
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But AZD 3759 only targets brain metastases with second-generation EGFR mutations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-(2,4,5-substituted anilino)pyrimidine compound and application thereof
  • 2-(2,4,5-substituted anilino)pyrimidine compound and application thereof
  • 2-(2,4,5-substituted anilino)pyrimidine compound and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1: N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-hydroxymethyl-indol-3-yl)pyrimidine- 2-yl]amino}phenyl)prop-2-enamide

[0106]

[0107] Step a: Preparation of 3-(2-chloro-pyrimidin-4-yl)-1H-indole (intermediate 1)

[0108] Dissolve indole (10.0g, 85mmol) in 1,2-dichloroethane (100mL), slowly add methylmagnesium bromide (3M, 28.5mL) dropwise at 0°C, after dropping, stir under ice bath After 15 minutes, 2,4-dichloropyrimidine (19.1 g, 128 mmol) was added to the above reaction solution all at once, and stirred overnight at room temperature. With stirring at room temperature, the above reaction solution was added dropwise to 1M dilute hydrochloric acid, a solid was precipitated, filtered with suction, and dried to obtain 11.0 g, with a yield of 56.3%.

[0109] Step b: Preparation of N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(indol-3-yl)pyrimidin-2-amine (intermediate 2)

[0110] Dissolve Intermediate 1 (11.0g, 48mmol), 4-fluoro-2-methoxy-5-nitroanil...

Embodiment 1A

[0124] Example 1A: N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-hydroxymethyl-indol-3-yl)pyrimidine- 2-yl]amino}phenyl)prop-2-enamide methanesulfonate

[0125]

[0126] At 70°C, to N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-hydroxymethyl-indol-3-yl) Pyrimidin-2-yl]amino}phenyl)prop-2-enamide (500mg, 0.97mmol) in a mixed solvent of ethanol (10mL) and EtOAc (8mL) was slowly added dropwise methanesulfonic acid (93mg, 0.97mmol) solution in EtOAc (4 mL). Keep stirring for 1.5 hours. Filtrate while hot, and dry in vacuo at 80° C. to obtain 530 mg of a light yellow solid with a yield of 89.3%.

[0127] ESI-MS m / z:516.4[M+H] + .

[0128] 1 H NMR (400MHz, DMSO-d 6 )δ:9.55(s,1H),9.26(s,1H),8.70(s,1H),8.56(s,1H),8.31(s,1H),7.67(d,J=4.0Hz,1H), 7.35(d, J=4.0Hz, 1H), 7.27(t, J=8.0Hz, 1H), 7.16(t, J=8.0Hz, 1H), 7.05(s, 1H), 6.73-6.66(m, 1H ),6.35-6.30(m,1H),5.82-5.79(m,1H),5.63(s,2H),3.88(s,3H),3.39-3.11(m,4H),2.82(d,J=4.0 Hz,6H),2.65(s,3H),2.32(s,3...

Embodiment 2

[0129] Example 2: N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methoxymethyl-indol-3-yl) pyrimidin-2-yl]amino}phenyl)prop-2-enamide

[0130]

[0131] N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-hydroxymethyl-indol-3-yl)pyrimidin-2-yl ]Amino}phenyl)prop-2-enamide (100mg, 0.194mmol) was dissolved in 2mL of dry DMF, NaH (9.3mg, 0.233mmol) was added under ice-cooling, after the addition was completed, it was reacted at 0°C for 0.5h, and then Iodomethane (33mg, 0.233mmol) was dissolved in DMF and added to the reaction solution, reacted at room temperature for 2h, the reaction solution was poured into water, extracted with DCM, the organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and column purified 25 mg of solid was obtained, yield: 24.3%.

[0132] ESI-MS m / z:530.4[M+H] + .

[0133] 1 H NMR (400MHz, CDCl 3)δ:10.49(s,1H),9.65(s,1H),9.29(s,1H),8.40(d,J=4.0Hz,1H),7.98(d,J=8.0Hz,1H),7.79( s,1H),7.55(d,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to certain 2-(2,4,5-substituted anilino)pyrimidine compounds as shown in a formula I which is described in the specification and an application thereof. The compounds or salts thereof exhibit higher inhibition to EGFR in an activated or drug-resistant mutant form than inhibition to wild-type EGFR. The toxicity associated with wild-type EGFR inhibition is reduced, so the compounds or the salts thereof are expected to have excellent pharmacodynamic properties, higher metabolic stability and better blood-brain barrier permeability, are more applicable to being used as a therapeutic agent, and are specifically applicable to being used for treatment of cancer. Therefore, the compounds or the salts thereof can be used for preparing medicines for treating EGFR-mediated diseases in certain mutant forms, especially medicines for non-small cell lung cancer.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a 2-(2,4,5-substituted anilino)pyrimidine compound and a pharmaceutically acceptable salt thereof, which selectively inhibit the activity of the epidermal growth factor receptor (EGFR) in a mutant form. The pharmaceutical composition of the compound and its pharmaceutically acceptable salt, and their application in the preparation of medicines for treating certain mutation forms of EGFR-mediated diseases, especially non-small cell lung cancer. Background technique [0002] Epidermal growth factor receptor (EGFR), a transmembrane protein tyrosine kinase of the erbB receptor family, binds to growth factor ligands such as epidermal growth factor (EGF), and the receptor binds to additional Homodimerization of EGFR molecules or heterodimerization with another family member (eg, erbB2 (HER2), erbB3 (HER3), or erbB4 (HER4)), homodimerization and / or heterodimerization of erbB receptors Dimerizatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D403/04C07D401/14C07F9/6558A61K31/506A61K31/675A61P35/00
CPCA61P35/00C07D401/14C07D403/04C07F9/65583
Inventor 范文华唐春雷范为正刘彦张晴
Owner 南京雷正医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com